Article Information
History
- June 15, 2024.
Article Versions
- Version 1 (June 13, 2024 - 05:37).
- You are currently viewing Version 2 of this article (June 15, 2024 - 06:48).
- Version 3 (November 4, 2024 - 14:31).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Thomas M Hallam1,2,*,
- Emanuela Gardenal1,2,
- Fraser McBlane3,
- GaEun Cho4,
- Lucy Lee Ferraro4,
- Eva Pekle1,5,
- Darlene Lu6,
- Kate Carney1,3,
- Claire Wenden1,3,
- Hannah Beadsmoore1,3,
- Sergio Kaiser5,
- Lauren Drage1,7,
- Thomas Haye1,7,
- Iris Kassem8,
- Nalini Rangaswamy8,
- Ma’en Obeidat5,
- Cyndy Grosskreutz2,
- Magali Saint-Geniez2,
- David H Steel9,
- Robert E MacLaren10,
- FOCUS Principal Investigators,
- Scott Ellis1,2,
- Claire L Harris1,2,
- Stephen Poor4,* and
- Amy V Jones1,4,*
- 1Gyroscope Therapeutics Ltd, A Novartis Company
- 2Translational Research, Ophthalmology, BioMedical Research, Novartis
- 3Pharmacokinetic Sciences, Translational Medicine, BioMedical Research, Novartis
- 4Clinical Development, Global Drug Development, Novartis
- 5Biomarker Development, Translational Medicine, BioMedical Research, Novartis
- 6Biostatistics, Global Drug Development, Novartis
- 7Cell and Gene Therapies, TRD, Novartis
- 8Ophthalmology, Translational Medicine, BioMedical Research, Novartis
- 9Bioscience Institute, Newcastle University, Newcastle Upon Tyne, UK; Sunderland Eye Infirmary, Sunderland, UK
- 10Nuffield Laboratory of Ophthalmology and Oxford Eye Hospital, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- ↵*Corresponding authors. thomas.hallam{at}novartis.com
Posted June 15, 2024.
Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration
